SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech Post author:Sam Post published:November 16, 2017 Post category:BioPharma A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace You Might Also Like AveXis Announces Proposed Public Offering Of Common Stock June 19, 2017 Repros Therapeutics Reports Fourth Quarter And Year End 2016 Financial Results March 30, 2017 Why Bay Area's Exelixis Surged 22% in January February 1, 2017